Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484329 | 0.79 | TRPV1 (0.48) | TRPV1SLC40A1TSHR | |
| SCHEMBL15661399 | 0.77 | TXNRD1 (0.32) | MCHR1TXNRD1GSRTRPV1THRA | |
| SCHEMBL4629666 | 0.70 | ALDH1A1 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3652029 | 0.69 | HTR2A (0.46) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL4629544 | 0.69 | ALDH1A1 (0.56) | THRATHRBHDAC3HDAC4HDAC1 | |
| SCHEMBL949595 | 0.68 | HTR2A (0.44) | SLC40A1HTR2AHTR6HTR1ADRD2 | |
| SCHEMBL27294618 | 0.67 | THRB (0.39) | TXNRD1GSRTHRATHRBHDAC3 | |
| SCHEMBL10634274 | 0.66 | THRB (0.50) | MCHR1THRATHRB | |
| SCHEMBL10834635 | 0.66 | THRB (0.45) | MCHR1TXNRD1GSRTHRATHRB | |
| SCHEMBL3258566 | 0.66 | MAPT (0.54) | TXNRD1GSRTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236947-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2011-09-29 | — | — | US | disclosed |
| US-7977337-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | GLAXO GROUP LIMITED | 2009-02-05 | — | — | US | disclosed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | MCHR1 152/4885TXNRD1 2668/4885GSR 1710/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | MCHR1 569/4885TXNRD1 1262/4885GSR 1137/4885 |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | MCHR1 78/4885TXNRD1 3411/4885GSR 2077/4885 |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | MCHR1 78/4885TXNRD1 3411/4885GSR 2077/4885 |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | HTR6, HTR3B, HTR4 | MCHR1 152/4885TXNRD1 2668/4885GSR 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.